Immunocore Holdings plc - ADR
IMCR
Market Cap$1.52B
Close$
$-0.33
101.1% downside
Current Fair Value
101.1% downsideOvervalued by 101.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.52 Billion |
|---|---|
| Enterprise Value | $1.50 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.02 |
| Beta | 0.76 |
| Outstanding Shares | 50,046,748 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -29.84 |
|---|---|
| PEG | -8.32 |
| Price to Sales | 4.97 |
| Price to Book Ratio | 4.26 |
| Enterprise Value to Revenue | 4.53 |
| Enterprise Value to EBIT | -24.3 |
| Enterprise Value to Net Income | -28 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 1.2 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Immunocore Holdings plc
2,020 employeesImmunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of disea...